Yuhan Corp.’s new anti-cancer drug Leclaza (ingredient: lazertinib), in combination with Janssen’s Rybrevant (ingredient: amivantamab), raised the response rate and extended the duration of response in advanced non-small cell lung cancer (NSCLC) patients who failed previous treatment.Researchers pre
Despite the prolonging Covid-19 pandemic, many Korean biopharmaceutical companies took part in the 2021 European Society for Medical Oncology (ESMO) Congress, one of the largest cancer meetings globally, to present their development of pipelines.ESMO presents the latest scientific developments in ba
Access Bio signed an agreement with PharmGen Science and New Jersey’s IVY Pharma to jointly develop a biosimilar of Covid-19 mRNA vaccine as part of the global vaccine partnership between Korea and the U.S.Under the accord, Access Bio and PharmGen Science will co-invest in IVY Pharma’s research on c
Sanofi-Aventis Korea said Thursday that oral biologic Dupixent (ingredient: dupilumab) has reaffirmed its efficacy in improving the quality of life of severe asthma patients by preventing symptom exacerbations.The company presented its study results at a recent online meeting hosted by the European
The government has recently authorized Covid-19 therapy Regkirona, developed by Celltrion, more than a year-and-a-half after the nation recorded the first confirmed case in early 2020.Now the challenge for most drugmakers here is more convenient oral therapy.The Ministry of Food and Drug Safety rece
With the number of pet owners growing and related industries enjoying a boom in Korea, local pharmaceutical companies are starting to advance into the veterinary drug market in earnest.The size of the domestic companion animal-related market grew from 900 billion won ($764.9 million) in 2012 to 5.8
Chinese pharmaceutical companies, armed with new drug technology developed by huge capital, are targeting the local market in earnest.China has been Korea's largest importer of raw materials for pharmaceuticals, but the world’s second-largest economy has rarely exported finished products to Korea un
JW Pharmaceutical said that it has launched Fuenpera, an influenza treatment in an intravenous (IV) injection, and has begun full-scale marketing activities.“Unlike oseltamivir, which patients have to receive orally for five days, Fuenpera uses peramivir hydrate as its main substance that treats the
Bridge Biotherapeutics said that it has presented the preclinical data of BBT-176, a non-small cell lung cancer (NSCLC) treatment, during the 2021 European Society for Medical Oncology (ESMO) Congress.“We have presented the preclinical research data related to the tumor suppression efficacy of BBT-1
Novo Nordisk said Thursday that its growth hormone formulation Norditropin (ingredient: somatropin) took the largest market share in 27 major countries in June. According to various international market research firms, including IQVIA and GERS, Norditropin dominated the growth hormone market in 27 c
GSK Korea said that the Ministry of Food and Drug Safety has approved Shingrix, its shingles vaccine.With the approval, hospitals can use Shingrix to prevent herpes zoster, also known as shingles, in adults over 50 or people over 18 who are at high or expected to have an increased risk of shingles d
Hugel said Wednesday that it had completed the U.S. Food and Drug Administration's mid-cycle meeting, an intermediate inspection process for the product approval review of its botulinum toxin (BTX) product, Letybo,"Before the meeting, the FDA conducted a current good manufacturing practice (cGMP) in
Eutilex and the National Cancer Center (NCC) have co-developed a strategy to increase the therapeutic effect of immunotherapy for solid cancer sharply.While existing immunotherapy showed a high cure rate for some hematologic cancers, it did not fully demonstrate its therapeutic effect in solid cance
Pfizer’s Lorviqua (ingredient: lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is expected to demonstrate less improvement in progression-free survival (PFS) in Asian patients, showing differences from existing ALK-TKIs.Pfizer is scheduled to release
HLB said its Chinese partner would showcase the efficacy of its anticancer drug candidate, rivoceranib, for various indications by presenting 13 study results at the European Society for Medical Oncology (ESMO) conference.The company expects Jiangsu Hengrui Medicine, which holds the marketing rights
JW Bioscience has signed a non-exclusive agreement to transfer its patented technology of multiple-biomarker complement factor b (CFB) and carbohydrate antigen 19-9 (CA19-9) to Sweden's Immunovia AB.The company developed the technology to detect pancreatic cancer early with a diagnostic kit using th
Hanmi Pharmaceutical said that it has confirmed the efficacy of LAPSGLP-2 Analog, a short bowel syndrome treatment, and published the study results during the 2021 European Society for Clinical Nutrition and Metabolism (ESPEN).LAPSGLP-2 Analog is a long-acting biopharmaceutical that applies with Han
Korean pharmaceutical companies have recently concentrated their R&D capabilities on developing drugs that treat urinary diseases, such as benign prostatic hyperplasia (BPH) and erectile dysfunction, that affect many elderly patients.According to industry watchers, such a move is inevitable to keep
Hanmi Pharmaceutical has decided not to give up on its anti-nicotine therapy and challenge Pfizer’s original treatment, Champix (ingredient: varenicline tartrate), once again.Earlier, the Korean company successfully released a treatment with the modified salt base but failed as it lost in the patent
Original drugs in the erectile dysfunction treatment market, such as Viagra and Cialis, failed to defeat generic copies in the second quarter, industry data showed.According to data from IQVIA, the size of the oral erectile dysfunction drug market in the second quarter was 29.5 billion won ($25.2 mi